Borderline Personality Disorder Clinical Trial
Official title:
Psychoeducation of Borderline Patients
Recent research suggests that BPD is a common, serious but treatable disorder with a better
than previously recognized prognosis. Despite these findings, many patients with BPD are not
given the borderline diagnosis by the mental health professionals treating them. It is also
true that many newly diagnosed borderline patients are not provided with up-to-date
information on the disorder even though psychoeducation has been found to be a useful form
of treatment for other serious psychiatric illnesses.
The investigators have conducted a preliminary randomized trial of psychoeducation for BPD
that found that those provided with immediate psychoeducation had a significantly greater
reduction in two core symptoms of BPD--general impulsivity and stormy relationships--than
those with delayed psychoeducation.
However, both instruction and assessment of change over time were conducted in person by
paraprofessionals. The importance of the current study is that it will allow the
investigators to develop and test the efficacy of an internet-based program of
psychoeducation for BPD that will be both cost efficient and easy to disseminate widely,
particularly to underserved populations.
Clinical experience suggests that many people with borderline personality disorder (BPD) are
not told of their borderline diagnosis by those treating them. Clinical experience also
suggests that many people with newly diagnosed BPD are not provided with up-to-date
information on the disorder. These practices are unfortunate as the results of a
preliminary, randomized, controlled trial of psychoeducation for BPD conducted by the
investigators suggest that informing patients about BPD soon after diagnostic disclosure may
be an effective form of early treatment for BPD as it significantly reduced the severity of
two of the core symptoms of borderline psychopathology—general impulsivity and unstable
relationships.
This application proposes building on the PI's prior work in this area by developing a
web-based program for the education of those with BPD and the assessment of three key
outcomes; psychoeducation and assessment of outcome that had previously been provided by a
team of clinically experienced research assistants. Both of these initiatives would allow
for the widespread, cost-efficient dissemination of this early form of treatment for BPD—a
form of treatment that has proven effective for other serious psychiatric illnesses.
The investigators first aim is to update our curriculum for teaching individuals with BPD
the latest information concerning the disorder. This information will be organized into
seven modules: introductory information (history of diagnosis, stigma associated with
disorder, and demographic characteristics associated with BPD), symptoms of BPD,
co-occurring disorders, etiology, longitudinal course, psychosocial treatments, and
psychotropic medications. Some modules will be divided into sub-modules. For example,
etiology will encompass childhood adversity, family history of psychiatric disorder,
temperament, genetics, and other biological findings.
The investigators second aim is to develop a website for teaching the most up-to-date
information about BPD and assessing three key outcomes: the severity of borderline
psychopathology, psychosocial impairment, and treatment utilization over time. These
outcomes will be assessed using self-report measures with proven psychometric properties.
Symptom severity will be accomplished through the internet-based administration of the
self-report version of the already widely used Zanarini Rating Scale for Borderline
Personality Disorder (ZAN-BPD)—a dimensional measure of the nine Diagnostic and Statistical
Manual of Mental Disorders, fourth edition(DSM-IV) symptoms of BPD. The investigators will
also use the Borderline Evaluation of Severity over Time (BEST) developed by Pfohl and Blum
as a secondary measure of change in severity of borderline psychopathology. Two other
self-report measures will be used to assess psychosocial impairment (Sheehan Disability
Scale and Weissman's Social Adjustment Scale). The use of nine forms of psychiatric
treatment will be assessed using a self-report version of the treatment section of the
Background Information Schedule and its follow-up analog.
The investigators third aim is to conduct a small-scale randomized controlled trial of
psychoeducation for BPD using this set of web-based instructional and assessment tools. Half
of the 80 subjects will be randomized to the investigators web-based intervention, which
will occur a week after diagnostic disclosure, and half will not. The investigators plan to
assess symptom severity, psychosocial impairment, and treatment utilization each week for 12
weeks (as the investigators did in our prior study) using the web-based self-report measures
described above to determine its immediate effects. The investigators also plan to assess
these outcomes using these measures at six months, nine months, and 12 months after
randomization to determine if these effects are long lasting. The investigators hypothesize
that two of the nine symptoms of DSM-IV BPD will decline significantly more in the subjects
who receive psychoeducation than those who do not-general impulsivity and unstable
relationships. The investigators further hypothesize that those in the treatment group will
have more improved functioning in the social and vocational (but not family realm) than
those in the non-treatment group. Finally, the investigators hypothesize that those
receiving psychoeducation will be more likely to seek out ongoing psychiatric treatment and
less likely to use emergency psychiatric services, such as hospitalizations, than those who
do not receive psychoeducation concerning BPD.
If successful, the results of this trial would provide further evidence that psychoeducation
is a useful form of early treatment for BPD. These results would also suggest that our
web-based platform is an effective and cost efficient method for delivering such a program.
Finally, these results would pave the way for a large-scale, multi-site randomized
controlled trial of this web-based program in community settings.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Active, not recruiting |
NCT04587518 -
Five Factor Model Treatment for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Completed |
NCT03677037 -
The Short-Term MBT Project
|
Phase 3 | |
Not yet recruiting |
NCT05989529 -
Delving Into Borderline Personality Disorder Clinical Trial Experiences
|
||
Completed |
NCT02068326 -
MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial
|
N/A | |
Completed |
NCT02518906 -
Evaluation of AIT Study
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Completed |
NCT02108990 -
Acetaminophen and Social Processes
|
Phase 2 | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT01635556 -
Evaluation of a Modified Dialectical Behavior Therapy Program
|
N/A | |
Completed |
NCT02988037 -
Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study
|
N/A | |
Not yet recruiting |
NCT01683136 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder
|
N/A | |
Completed |
NCT02397031 -
Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder
|
N/A | |
Terminated |
NCT01103180 -
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
|
Phase 2 | |
Terminated |
NCT01212588 -
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
|
Phase 2 | |
Terminated |
NCT00539188 -
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
|
Phase 2 | |
Recruiting |
NCT05398627 -
Neurofeedback for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT03994510 -
SHame prOpensity in bOrderline Personality Disorder
|
N/A | |
Recruiting |
NCT06005129 -
Personality Change Study for Borderline Personality Disorder
|
N/A |